From: Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
Response
Responses at the end of induction, week 12 (N = 69)* n (%)
Responses across all treatment phases (N = 69)* n (%)
CR
1 (1.5)
3 (4.3)
PR
5 (7.2)
6 (8.7)
SD
15 (21.7)
13 (18.9)
PD
48 (69.6)
47 (68.1)
ORR
9 (13.0)
DCR
N/A
22 (31.9)